An interview with Dr. Harold Burstein from Dana Farber Cancer Institute in Boston, MA, chair on “Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast ...

In 2021, ASCO published a guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer that is either ...